Axcelis Technologies, Inc. (ACLS) AI Stock Analysis

Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment essential for semiconductor chip fabrication across the United States, Europe, and the Asia Pacific regions. The company offers high energy, high current, and medium current implanters tailored for specific semiconductor manufacturing applications. Axcelis also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company markets its products and services primarily through a dedicated direct sales force to build direct engagements with semiconductor chip manufacturers globally.

Axcelis achieved peak annual revenue of $1.13B and net income of $246.3M in FY2023 before contracting. Revenue fell 10.0% in FY2024 to $1.02B, and fell 17.6% in FY2025 to $839.0M, with net income declining to $120.2M and operating margin reducing from 23.5% in FY2023 to 14.2% in FY2025. Despite revenue reductions, gross margin widened slightly to 44.9% in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $866.1M with an operating margin of 9.4% and diluted EPS of $2.98. In the quarter ended June 30, 2026, quarterly revenue increased 10.6% year-over-year, while quarterly earnings declined 23.5%.

As of June 30, 2026, Axcelis reported $402.2M in cash and short-term investments against $41.6M in total debt, yielding net cash of $360.6M. Liquidity is supported by a current ratio of 4.90 and a low debt-to-equity ratio of 0.04 on $1.07B in shareholders' equity. In FY2025, the business generated $118.3M in operating cash flow and $107.0M in free cash flow. Capital allocation in FY2025 included $11.3M in capital expenditures and $121.1M in share buybacks, contributing to an 8.5% reduction in share count over 5 years.

ACLS trades at a trailing P/E of 36.4x and a forward P/E of 19.8x, compared to medians of 28.1x and 18.8x for its US-listed Technology peers. Its enterprise value stands at $3.30B, trading at an EV/EBITDA of 24.9x versus the peer median of 16.6x, and a price-to-sales multiple of 3.9x compared to 2.8x for peers. Over the past year, the stock returned 29.6%, outperforming the 16.8% return of the S&P 500 (SPY). Over a 5-year span, ACLS gained 119.5% versus 83.0% for SPY.

Wall Street coverage consists of 1 Strong Buy, 0 Buy, 3 Hold, and 1 Sell recommendations. The mean price target is $161.00, representing 48.6% upside over the last close of $108.35. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $883.5M and EPS of $4.11, implying a 15.9% decline in earnings. For the following fiscal year, 5 analysts expect revenue to rise 11.9% to $988.8M with EPS growing 28.3% to $5.27. Axcelis has beaten EPS expectations in each of the last 4 quarters, with next earnings scheduled for November 3, 2026.

This page is an AI-written research summary of Axcelis Technologies, Inc. (ACLS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACLS income statement, ACLS balance sheet, ACLS key metrics, ACLS analyst forecast, ACLS chart. See the ACLS stock overview for the latest quote and news.